RuxoBEAT
RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera

Released: December 13, 2023

Activity

Progress
1
Course Completed